Clinical and economic analysis of pharmacotherapy of children with acute nasopharyngitis
DOI:
https://doi.org/10.24959/sphhcj.16.54Keywords:
drugs for the treatment of acute nasopharyngitis, clinical and economic analysisAbstract
The analysis of 47 medical records of children with the diagnosis of acute nasopharyngitis, who received treatment of common forms of acute respiratory viral infections – acute nasopharyngitis (ANP) during August 2015 – January 2016 has been conducted. For the treatment of children 75 drugs from 39 INN belonging to 15 pharmacotherapeutic groups were prescribed. According to the integrated ABC /VEN / frequency analysis it has been determined how irrational prescriptions affected the amount of the money spent on inappropriate ANP pharmacotherapy in children. According to the results of formal VEN-analysis conducted by the National Drug Formulary of Ukraine (NDFU)/unified clinical protocols of the primary care (UCPPC) of adults and children with acute respiratory infections it has been found that the group of non-essential drugs contained 9/26 INN drugs with “N” index, they were prescribed 82/145 times (35.04/64.01% of the total prescriptions – 234), respectively, and their costs were 38.64 and 63.91% of the total cost of pharmacotherapy per 47 patients – 16,365.08 UAH. Both medical regulatory documents did not contain 4 INN drugs that were prescribed 11 times (4.70%), and costs for them were 3.67% of the total cost for the pharmacotherapy. Therefore, in this medical preventive institution the optimization of costs for ANP pharmacotherapy is necessary by reducing prescriptions of non-essential drugs according to medical regulatory requirements: NDFU (the 7-th edition, 2015) and UCPPC of adults and children with acute respiratory infection (2014).
References
Воробьев, П. А. Клинико-экономический анализ в медицинской организации. Практическое руководство для лиц, принимающих решения / П. А. Воробьев // Рациональная фармакотерапия. – 2009. – № 1 [Электронный ресурс]. – Режим доступа: – http://rpht.com.ua/ru-issue-article-1202
Гордиенко, С. Грипп и простуда: выбираем правильное лекарство / С. Гордиенко // Еженедельник Аптека. – № 777 (6) от 14.02.2011 г. [Электронный ресурс]. – Режим доступа: http://www.apteka.ua/article/72050
Державний формуляр лікарських засобів. Випуск сьомий. – К.: ДП «Державний експертний центр МОЗ України», 2015. – 1201 с.
Майоров, Д. В. Клинико-экономический анализ применения иммунокорригирующих препаратов для профилактики респираторных инфекций и их осложнений у часто болеющих детей младшего школьного возраста / Д. В. Майоров, Д. П. Дербенев // Проблемы социальной гигиены, здравоохранения и истории медицины. – 2014. – № 6. – С. 23–26.
Наказ МОЗ України від 16 липня 2014 р. № 499 «Уніфікований клінічний протокол первинної медичної допомоги дорослим та дітям на гострі респіраторні інфекції». [Електронний ресурс]. – Режим доступу: https://drive.google.com/file/d/0BwOe009aXWxBSk1TcThhZmdxSkk/view
Пипа, Л. В. Гострі респіраторні вірусні інфекції та грип: клініка, діагностика, профілактика / Л. В. Пипа // Новости медицины и фармации. – 2008. – № 2 (233) [Електронний ресурс]. – Режим доступу: http://www.mif-ua.com/archive/article/4384
Пневмония – причина 20% случаев детской смертности / Материалы ВОЗ от 12 ноября 2013 г. [Электронный ресурс]. – Режим доступа: http://www.who.int/mediacentre/news/releases/2013/world-pneumonia-day-20131112/ru/
Сирко, Ж. Страховщики подсчитали стоимость лечения гриппа и ОРВИ / Ж. Сирко // Главздрав. – Выпуск от 26.10.2015 [Электронный ресурс]. – Режим доступа: http://www.glavzdrav.com.ua/c24sx/562df66a0cf213dceace0e35
Современные возможности иммуно-профилактики острых респираторных инфекций у часто болеющих детей / Н. А. Коровина, А. Л. Заплатников, И. В. Леписева и др. // Педиатрическая фармакология. – 2008. – Т. 5, № 1. – С. 21–25.
Эксперт про грипп и стоимость его лечения / Голос Столицы от 19.01.2016 г. [Электронный ресурс]. – Режим доступa: http://newsradio.com.ua/rus/ 2016_01_19/JEkspert-pro-gripp-istoimost-ego-lechenija-6688/
Downloads
Published
Issue
Section
License
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
